Pfizer Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-99.9% vs price
Base Case (Median)
-99.9% vs price
Bull Case (75th pct.)
-99.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $21.58 | -99.8% | High (40%) |
| PE Comparable | $13.07 | -99.9% | Medium (25%) |
| Graham Number | $7.11 | -99.9% | Medium (40%) |
| EV/EBITDA | $3.85 | -100.0% | Medium (20%) |
| EV/FCF | $7.91 | -99.9% | Medium (20%) |
| Earnings Power Value | $4.54 | -100.0% | Medium (50%) |
Based on 6 out of 8 methods, PFE.BA appears overvalued at the current price of $9770.00. The base case fair value of $7.51 implies 99.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.